<SEC-DOCUMENT>0001104659-26-048010.txt : 20260424
<SEC-HEADER>0001104659-26-048010.hdr.sgml : 20260424
<ACCEPTANCE-DATETIME>20260424060313
ACCESSION NUMBER:		0001104659-26-048010
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20260424
FILED AS OF DATE:		20260424
DATE AS OF CHANGE:		20260424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evotec SE
		CENTRAL INDEX KEY:			0001412558
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34041
		FILM NUMBER:		26890333

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		ESSENER BOGEN 7
		CITY:			HAMBURG
		PROVINCE COUNTRY:   	2M
		ZIP:			22419
		BUSINESS PHONE:		49-40-560-810

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		ESSENER BOGEN 7
		CITY:			HAMBURG
		PROVINCE COUNTRY:   	2M
		ZIP:			22419

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Evotec AG
		DATE OF NAME CHANGE:	20070917
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2612670d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the month of April, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMISSION FILE NUMBER 001-34041</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Evotec
SE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B></B></FONT><FONT STYLE="font-size: 10pt; color: #333333">(Translation of registrant&rsquo;s name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Essener Bogen 7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>22419 Hamburg</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Tel:
+49 40 560810<BR>
</B></FONT><FONT STYLE="color: #333333">(Address of principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT>
Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2026, Evotec SE (the &ldquo;Company&rdquo;) </FONT>submitted a press release announcing Chief Financial Officer Transition attached
hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit</U></B></FONT></TD><TD><B><U>Description
                                            of Exhibit</U></B></TD></TR>
                                                                                                                                          <TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"><A HREF="tm2612670d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD><TD><A HREF="tm2612670d1_ex99-1.htm" STYLE="-sec-extract: exhibit">Evotec Announces Chief Financial Officer Transition</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Evotec SE</B></FONT></TD></TR>
  <TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Christian </FONT>Wojczewski</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT> Christian Wojczewski</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 24, 2026</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2612670d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="tm2612670d1_ex99-1img001.jpg" ALT=""></FONT><P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evotec Announces Chief Financial Officer Transition</FONT></P>

<P STYLE="font: bold 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Hitchin to step down as of April 30, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claire Hinshelwood appointed to CFO role as of May 1, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hamburg,
Germany, April 24, 2026</B> &ndash; Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced that Chief Financial Officer
(CFO) Paul Hitchin will step down on April 30, 2026, for personal reasons unrelated to the company. The Supervisory Board has accepted
Mr. Hitchin&rsquo;s decision and expressed deep appreciation for his leadership and significant contributions to the company. Since March
1, 2025, he successfully led Evotec through a significant financial and strategic evolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Hitchin will be succeeded by Claire Hinshelwood, effective May 1, 2026<I>. </I>Ms. Hinshelwood has more than 30 years of experience in
financial leadership positions, most recently as Group Chief Finance Officer of BMI Group. In this role, she transformed the company&rsquo;s
financial operations and delivered significant underlying improvements to its financial position during a period of challenging market
conditions. She has also served as Global Head of Finance Operations at Novartis and held positions of increasing responsibility at Syngenta,
including Head of Business Services for Latin America and Head of Finance for the East Europe and Asia-Pacific regions. Ms. Hinshelwood
holds a B.A. in Accountancy and Finance from Heriot-Watt University and is a member of the Chartered Institute of Management Accountants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
Christian Wojczewski, Chief Executive Officer of Evotec, said:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;I
would like to express my sincere thanks to Paul for making substantial contributions to Evotec&rsquo;s progress during his tenure as
Chief Financial Officer. He has been a highly valued collaborator and advisor who has managed the company&rsquo;s finances with skill
and insight and supported our strategic advancement during a period of transformation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we continue to transform our business and operations, I look forward to working with Claire to continue Evotec&rsquo;s pursuit of its
near- and mid-term goals. Her financial expertise and record of positive change in leadership positions across multiple industries put
her in an excellent position to advance our progress toward increased profitability and sustainable growth.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> of 2</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="tm2612670d1_ex99-1img002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Paul
Hitchin, Chief Financial Officer of Evotec, said:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;My
tenure at Evotec has been extremely rewarding. I&rsquo;m deeply grateful to everyone for their dedication and hard work in our transformation
journey, especially the teams I had the opportunity to lead. I&rsquo;ve had the privilege of being at the forefront of a multifaceted
company transformation, building what will be a more agile, commercially dynamic and profitable business. I leave Evotec with great confidence
in the direction we have set and in the company&rsquo;s path toward a new phase of growth and value creation.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Claire
Hinshelwood, Evotec&rsquo;s designated Chief Financial Officer, added:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;I
look forward to working with the Evotec team as they continue to execute the transformational plan that will deliver on sustainable and
profitable growth. Evotec is uniquely positioned to accelerate the R&amp;D engine that drives the discovery of new medicines and their
advancement into the clinical pipeline, creating tremendous business potential as new discoveries and technologies transform the life
sciences sector. I am very excited to join the team and &ndash; together with colleagues across the organization &ndash; to help Evotec
realize its full potential.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>About
Evotec SE</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evotec
is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven
innovation and advanced technologies, we accelerate the journey from concept to cure &mdash; faster, smarter, and with greater precision.
Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as
Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers&rsquo;
needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings
range from standalone services to fully integrated R&amp;D programs and long-term strategic partnerships, combining scientific excellence
with operational agility. Through Just &ndash; Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility
and affordability. With a strong portfolio of over 100 proprietary R&amp;D assets, most of them being co-owned, we focus on key therapeutic
areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec&rsquo;s global team of more than 4,500
experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence.
Learn more at <U>www.evotec.com</U> and follow us on <U>LinkedIn</U> and X/Twitter <U>@Evotec.</U></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>Forward-looking
statements</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec&rsquo;s
securities. Words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
 &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo;
 &ldquo;would&rdquo; and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements
include comments regarding Evotec&rsquo;s expectations for revenues, Group EBITDA and unpartnered R&amp;D expenses. These forward-looking
statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these
statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known
and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties
and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release
publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec&rsquo;s expectations
with respect thereto or any change in events, conditions or circumstances on which any statement is based.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal"><B>Investor
Relations and Media Contact</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Sarah Fakih<BR>
EVP Head of Global Communications &amp; Investor Relations<BR>
<U>Sarah.Fakih@evotec.com</U></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 2</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2612670d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2612670d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !( +X# 2(  A$! Q$!_\0
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MT6CI;Z8]S#I'C/XEFS<0>,OB/=6\\ES)<WCW.C>%#=3:5X4MK>,W^IZO^^>
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MW&DV,]Q.+6<+:MX)\=_^"PW[+WP;^*>K?!+PKX?^+O[0OQ0T"ZN=/U_P_P#
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M;[98VVJB74-)TFROKFRVZC_8Z:E<Z_%IDEOJ4FD"SO+&6Y /T4HK\Y?V:_\
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M.BZSI>I:E'/)I5P^I64UO:2P/KEMH[>8$]2_82_;5_:0_;/\/_%CXIZ5\"?
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M K\G_P#@X-\%>)_'O_!'3]N30_",%W/JEA\./"_C*Z2SCDFF_P"$9^'/Q4\
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M?HOA[P[I=EHNAZ180 B&RTS2M-@MK&PM(@2([>U@BA3)VH,FMJB@ HHHH 3
MY/<]^_YT8^OYG_&BBE9=E]R?YW ,#KW]?\_7I67KFAZ/XET;5O#OB'3+#6]
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<#-0HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2612670d1_ex99-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2612670d1_ex99-1img002.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  J &L# 2(  A$! Q$!_\0
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MRVW@[PE?O#)J.D>'O"?@CP_X,\'I<ZL]O;2ZSKNIZ'J>NW\\".-0MT+Q'0\
M_L7?!;X:_M1_%;]K?PM:ZW:_$[XP>'+?P[XDTZ2YTH>#M.R_A^77-:\/:1:Z
M+:W]AKWBZY\+Z'>>*K^ZUB_&J7UF]VL-O-=WC3_GIUGP/\!_V9?AQ^V_K7[7
MWQH_:(N/%GBWQJO[2?QH^!WPS@E\7>(=-C_9[\)_"35&\)^&6^'.GZ5J=E:>
M'?&C2JGB;5];CC>2ZU$6DBQ1&XUF35_S9\>);?M%_L5_\$Y?'OQFNKOXH_$+
M3O\ @H5X(_9?U?XIZCK_ (BGO/B1\*;#QE\4H!/<3G5E-R^KV-GI4$WB*4R>
M)9YM,DNFUD375R7_ '@\;_L$>%M<\9?$WQ;\./CK^T+\ ;3XW7TVI_&3P;\(
M?%WAFP\'>.-7O[*+3M:\36VF>*O!GBNY\%>,_$%G!!!KGBSP/?:!JFI",3W+
M/>D78T?'/_!/O]G_ ,5_LW_#K]F/P_:>)OAGX,^#GBGP]X^^$GB#P+K9M_&/
M@/XA>&;[5=2L/&UCJFMVVM6VJZW=7VO:]<:L^NV.I07TNLWMRD5M?)8W=D ?
M#/[1GAR34OVR?A=^R=H?[.7BKX]? +X,?LEQ_$S1/@+I'Q/\->#_  UJ/B+Q
M'\2;_P "VGB[Q:WQ(\:Z#;>.=/\ !&D: ND:)IVI:AK5WIVL>)[G5/L\( GG
MY_QIKG[3O[*G["W[;\\G@GQA^S_X53QQX&M/V9H/$OQ.\*?$/Q'\(_!/QHUS
MP#\/?&]AI6O^#/%OBI]%T+X<>(M:\1>)/ T<VH0W>D6^LV4-E+#%INZR_1CQ
M]^QM8^/E^%?BMOC?\9/"7QZ^$_A6^\&:=^T3X-O?!>D_$#Q9X;UE[:YU[0?'
MFBW/@[4/A_XET+5-2M+76DTB?PE#!I&LV\6HZ*^GS/=_:MCPK^QA\)M)^#OQ
M5^#?C;4?'/QFT[XZW.I:C\9/%OQ6\3S:]XR\=ZMJ6G6.EI?S7^G6^CZ;X<&A
MV&EZ3:^%++PCI6A6/AI-)TV;38([VW-W( >?> /^">_P@^#'C[X3_$3X)^)/
M'7PN\1>"EO=/^(<NG^)=3U]/VA=(O])%O=6'Q8@\5WVL6NL:A_:4'_"0VNN6
MEM!JVF7KW1TN:R"V4FG_ 'Q7PI\-/V$M \%>./A]XT\=?'O]H?X^1_!T7;_!
M_P +_&3Q?X;U;PYX$U&[T]M'7Q$\'AGP?X6O?%_BJPT>6?2](U[QE>ZW/I5M
M=7,MI$M_(E[%]UT (1G_ #_G_/<4S )(SCUQU/U.![<G.>Y..)**SG&,G'F5
M[MI7MI[K3:OJKIM7BX/NVM@C9..W7TXP,X&,'UR<8/ )SS7^=U_P<N?\$5OC
MMX.^.WQU_P""EWPEG\->,O@#\0[OP]XL^+.AR:Y8:'XU^%'BG^QM$\*:KJ1T
MO69+&V\7>$?$FK6%IJEG/X;OK_Q+I^J:W?:=>>&TTG3H=;NO]$FD(!!! (.<
M@@$'/7([Y[U^J>#7BWQ%X+<91XLX<I83%QK4(Y;GF4XZ%\+G.43Q-'&5<(ZT
M(^VP6*A7HQK8+,*/M:V#KWE[*O1G5P]3AS# TLQP_L*SE&TN:E4B_>IU.5Q4
MK/246M)0=E)=4TI+_.M_X-I?^"*7QA^)'QK^#?\ P4E^,5YI?@GX$_"W6[[Q
M=\'=#LM5T?7?%7Q?\:Z;%JFA65Y<6FEW]V/!?A#PIJLDNI7LVO+;^(M:U33;
M/3M/T1-)NY]<M_\ 12  Z9_'\/\ "D  P    < # &",8 XXIU:>,7BYQ'XT
M<8U>+.(:>&PD*&%669%E&#5\-DN30KU,13P<<1*$*^.Q-6O4GB<=F&)4:V,Q
M,O:>RP]*%+#P,OP%++L.J%)N5Y<]6<MZE1I)RMM&*248P6D8Z7;NV4445^5G
4<'^?\_YS1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
